KPTI
Karyopharm Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.79
+1.13%Aug 31, 2026, 11:30 UTC
Karyopharm Therapeutics submitted a supplemental New Drug Application to the U.S. FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis.
Source:Aug 13, 2026, 13:51 UTC
Karyopharm Therapeutics reported a Q2 2026 loss of $2.32 per share, missing the Zacks Consensus Estimate of a loss of $1.53, and compared to a loss of $4.32 per share a year ago.
Source:Jul 30, 2026, 20:06 UTC
Karyopharm Therapeutics plans to submit a supplemental New Drug Application to the FDA in August 2026 for accelerated approval of selinexor plus ruxolitinib for myelofibrosis.
Source:Jul 30, 2026, 20:05 UTC
Karyopharm Therapeutics announced topline results from its Phase 3 XPORT-EC-042 trial evaluating selinexor in endometrial cancer, which did not meet the primary endpoint.
Source: